A new biotech business has been launched in Oxford to tackle one of the world’s rarest diseases.
SynaptixBio is working to develop the world’s first treatment for TUBB4a leukodystrophy, including H-ABC – a debilitating and potentially life-limiting neurodegenerative condition.
To continue reading please go to the article on Business & Innovation Magazine